In general the comprehensiveness of the coverage of issues relating to opioid agonist substitution treatment is impressive. Besides addressing the practical issues of pharmacology, program structure and orientation, dosing, and related topics, the book also presents an illuminating history of narcotics control in the U.S. as well as an informative chapter on regulatory and policy issues. The latter chapter is particularly relevant because the regulation of opioid agonist substitution treatment is in flux; the Center for Substance Abuse Treatment (CSAT) is assuming oversight from the Food and Drug Administration, and it is already pilot-testing an accreditation process that likely will have a significant impact on how programs are managed. Initiatives are also under way to try to broaden the availability of treatment through office-based prescribing by individual physicians. Also under way is a cooperative pilot program of the Department of Veterans Affairs, the National Institute on Drug Abuse, and CSAT studying office-based prescribing of buprenorphine.